Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Key Highlights
- ➤Novavax (NVAX) earns $125 million milestone as Sanofi begins Phase 3 combination-vaccine trial
- ➤Sanofi evaluates Nuvaxovid with Efluelda/Fluzone High-Dose in European adults aged 60 and older
- ➤Novavax eligible for $75 million manufacturing-transfer milestone anticipated in mid-2027
- ➤Novavax eligible for additional $225 million milestone after potential U.S. combination-vaccine launch
- ➤Sanofi partnership has generated over $1 billion in revenue for Novavax
Expert Statements
John C. Jacobs, President and Chief Executive Officer, Novavax
“Novavax and Sanofi continue to successfully execute on the opportunities afforded by our partnership. To date, the partnership has generated over $1 billion in revenue for Novavax,”
John C. Jacobs, President and Chief Executive Officer, Novavax
“Sanofi has stated that they intend to be one of the first movers in the combination vaccine segment, and Novavax believes this is an important step toward that goal. We are excited about the value we are building together with our partners.”
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe PR Newswire
* The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease(1) * The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine * Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™. Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone(®) High-Dose vaccine in adults aged 60 and older.
Get started
Create a free account to read the full story.